A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Authors

Jann Sarkaria

Published

June 1, 2024

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Randomized Controlled Trial

DOI

10.1200/jco.2024.42.16_suppl.2017

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Authors

Jann Sarkaria

Published

June 1, 2024

Share your thoughts on this paper...

Supporters

Support the authors with ResearchCoin

Journal

Journal of Clinical Oncology

Topics

Randomized Controlled Trial

DOI

10.1200/jco.2024.42.16_suppl.2017

Paper

Paper

Paper

Paper

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Supporters

Journal

Topics

DOI

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

Supporters

Journal

Topics

DOI